/ /

  • linkedin
  • Increase Font
  • Sharebar

    Exploring safety, efficacy of high-intensity focused ultrasound in glaucoma

    New circular cyclocoagulation technique is noninvasive, repeatable and relatively pain-free

    Noninvasive glaucoma procedures (NIGPS) represent a new dawn in the management of glaucoma, as they try to fill the gap between the shortcoming of glaucoma surgeries and antiglaucoma medications.1

    High-intensity focused ultrasound (HIFU) cyclocoagulation is a NIGPS that was introduced in the 1980s by Coleman et al. to selectively destroy ciliary body tissue and reduce aqueous humour production.2-4

    Recently, the development of a new circular cyclocoagulation device, which uses miniaturised transducers to produce HIFU (EyeOP1 EyeTechCare, Rillieux-la-Pape, France), has renewed interest in the technique (see Figure 1).5,6 The procedure can also be defined as ultrasound ciliary plasty (UCP).

    Parameters used are: 21 MHz operating frequency; six activated sectors; 2 to 3 W acoustic power; 8 seconds of the HIFU delivery time for each sector; and three different probe sizes (11-, 12- or 13-mm ring diameters) selected for each eye using preoperative biometric data based on AS-OCT image.7

    Clinical trials in humans have shown that the device allowed a significant and predictable IOP reduction with a good local tolerance after one UCP treatment.5-8

    In this study we aimed to evaluate success rate, long-term effectiveness and safety of multiple UCPs (up to three times per eye) in patients who experienced a lack of efficacy or incomplete success with prior glaucoma therapies.

    Dr Antonio Toso

    Dr Antonio Toso is the director of the Vitreo?Retinal Surgery Unit in the Ophthalmic Department of the St Bassiano Hospital in ...

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results